A version of this post originally appeared on the blog for PACE Network, a Lilly Oncology initiative.
Over the past 25 years, the picture of life after a cancer diagnosis has changed drastically. Thanks to medical advances, millions of people living with cancer have been able to experience a better quality of life, spend more time in the company of loved ones, and even overcome illness. However, sustaining this momentum and accelerating the pace of cancer innovation requires a better understanding of how existing cancer innovations bring value to the health care community. That's why we're excited to announce the upcoming release of the PACE Continuous Innovation Indicators™ (CII). This new, first-of-its-kind resource will help measure the progress we've made against cancer over time and illuminate challenges and gaps yet to be addressed.
Today, let's take look at some of the common questions about the Continuous Innovation Indicators™:
- Why have we created a tool to measure continuous innovation? Mounting concerns about increasing health care costs have fueled a wide debate about what progress and value in cancer care really look like. As the CII's authors note, "Stakeholders lack tools to visualize and otherwise express differences in values, which ultimately leads to different decisions about research and health spending priorities." The CII tool will help address this concern by presenting a new, objective way to look at advances in cancer care and treatment.
- How does the CII tool work? The Continuous Innovation Indicators™ tool compiles thousands of pieces of evidence, gathered by trained analysts, from clinical trial records, meta-analyses, and observational studies. It then generates graphs to help users understand how innovation has helped improve the patient outlook across twelve tumor types over the last four decades.
- How can the CII tool be used to accelerate innovation? The CII will make it possible for policymakers, health policy experts, and patient advocates to visualize progress against cancer over time, gain a better understanding of how value in cancer treatment evolves, and consider the potential impact of policy reforms on the speed of innovation.
The idea that we are winning--or losing--the war on cancer ignores the reality: cancer is a complex set of diseases, each with its own complex journey. We hope that the CII tool will be used to understand how far science has come, as well as where we need to focus our efforts in the future.